Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.59 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.53 |
| ▸ | BRAF | P15056 | 3/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 6/20 | 0.49 |
| ▸ | KIT | P10721 | 6/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.48 |
| ▸ | WNT1 | P04628 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980775 | 0.88 | SUCNR1 (0.52) | HPGDSSUCNR1BRAFCHRM3DDR1 | |
| SCHEMBL27964239 | 0.86 | HDAC6 (0.55) | HPGDSSUCNR1BRAFCSF1RKIT | |
| SCHEMBL6782706 | 0.85 | HPGDS (0.75) | HPGDSSUCNR1BRAFCSF1RKIT | |
| SCHEMBL31721202 | 0.85 | HPGDS (0.69) | HPGDSSUCNR1BRAFDDR1CSF1R | |
| SCHEMBL4831878 | 0.84 | WDR5 (0.60) | HPGDS | |
| SCHEMBL7611262 | 0.84 | HPGDS (0.68) | HPGDSSUCNR1BRAFCSF1RKIT | |
| SCHEMBL30530313 | 0.83 | HDAC1 (0.62) | HPGDSSUCNR1BRAFBTKHDAC1 | |
| SCHEMBL31721288 | 0.83 | HPGDS (0.59) | HPGDSBRAFCHRM3DDR1CSF1R | |
| SCHEMBL6780729 | 0.83 | HPGDS (0.67) | HPGDSBRAFCSF1RKITBTK | |
| SCHEMBL6966564 | 0.81 | HPGDS (0.65) | HPGDSBRAFCSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| CN-1185211-C | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2005-01-19 | — | — | CN | disclosed |
| CN-1178932-C | Amide derivatives | — | 2004-12-08 | — | — | CN | disclosed |
| CN-1146542-C | Benzamide derivatives and their use as cytokine inhibitors | — | 2004-04-21 | — | — | CN | disclosed |
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | disclosed |
| CN-1319092-A | Benzamide derivatives and their use as cytokine inhibitors | ASTRAZENECA AB (SE) | 2001-10-24 | — | — | CN | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| CN-1300278-A | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2001-06-20 | — | — | CN | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| CN-1271279-A | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LTD (GB) | 2000-10-25 | — | — | CN | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | HPGDS 648/4885SUCNR1 1324/4885BRAF 3175/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | HPGDS 648/4885SUCNR1 1324/4885BRAF 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.